Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 3 versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 3 versus NILSTAT.
MICONAZOLE 3 vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability, leakage of cellular contents, and fungal cell death.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
For vaginal candidiasis: 200 mg (one suppository) intravaginally at bedtime for 3 consecutive days.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal half-life is approximately 24 hours (range 20-30 hours) following topical vaginal application; prolonged in hepatic impairment.
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Primarily hepatic metabolism; <1% excreted unchanged in urine; fecal elimination accounts for ~50% of metabolites.
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category A/B
Category C
Antifungal
Antifungal